Surrozen (NASDAQ:SRZN) Director Acquires $353,819.20 in Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 18,052 shares of the stock in a transaction dated Tuesday, January 20th. The stock was acquired at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the transaction, the director owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This trade represents a 1.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Tim Kutzkey also recently made the following trade(s):

• On Friday, January 16th, Tim Kutzkey bought 2,562 shares of Surrozen stock. The shares were bought at an average cost of $20.00 per share, with a total value of $51,240.00.
• On Thursday, January 15th, Tim Kutzkey purchased 11,893 shares of Surrozen stock. The stock was purchased at an average cost of $19.89 per share, for a total transaction of $236,551.77.
• On Wednesday, January 14th, Tim Kutzkey acquired 5,523 shares of Surrozen stock. The stock was purchased at an average price of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey acquired 12,470 shares of Surrozen stock. The shares were acquired at an average cost of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey bought 15,100 shares of Surrozen stock. The stock was acquired at an average price of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Tim Kutzkey purchased 30,884 shares of Surrozen stock. The stock was acquired at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey purchased 5,266 shares of Surrozen stock. The shares were acquired at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The stock was purchased at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Trading Down 10.1%

NASDAQ SRZN traded down $2.02 during trading hours on Tuesday, reaching $17.98. 62,608 shares of the stock traded hands, compared to its average volume of 59,333. The stock has a 50 day simple moving average of $18.98 and a two-hundred day simple moving average of $14.13. Surrozen, Inc. has a 1 year low of $5.90 and a 1 year high of $24.94.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The firm had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Research analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Surrozen

A number of institutional investors have recently bought and sold shares of SRZN. Citadel Advisors LLC lifted its position in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares in the last quarter. Armistice Capital LLC bought a new position in shares of Surrozen during the 2nd quarter valued at approximately $536,000. Woodline Partners LP purchased a new stake in Surrozen in the 3rd quarter worth approximately $621,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Surrozen during the 3rd quarter worth approximately $889,000. 66.57% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on SRZN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.